[Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma].
Cladribine is a purine analogue that is resistant to degradation by adenosine deaminase. We describe the efficacy of cladribine monotherapy in 8 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The median age of the patients was 57 years. All patients were given 1-3 courses of cladribine monotherapy at 0.09 mg/kg/day continuous infusion for 7 days. Although all patients had been treated with rituximab and CHOP-like regimens, the response rate was excellent (85.7%). Thus we consider that cladribine is the first treatment of choice in the patients with relapsed or refractory indolent lymphoma.
Nakashima
Yasuhiro
Y
Department of Hematology, National Hospital Organization Kyushu Cancer Center.
Shimada
Toshihiro
T
Yamada
Yu
Y
Choi
Ilseung
I
Yufu
Yuji
Y
Uike
Naokuni
N
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017338:Cladribine / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D017338:Cladribine